Clinical Scorecard: Oculis Discusses Genotype-Based PREDICT-1 Trial of Licaminlimab
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry eye disease; licaminlimab is being developed for TNFR1-mediated dry eye disease. |
| Key Mechanisms | Licaminlimab is a TNF-α inhibitor. PREDICT-1 includes patients positive for a specified genetic variant of TNF receptor 1 (TNFR1). |
| Target Population | Patients with dry eye disease enrolled in PREDICT-1; approximately two-thirds are expected to have the specified TNFR1 genotype. |
| Care Setting | Phase 3 clinical-trial evaluation of licaminlimab for dry eye disease. |
Key Highlights
- PREDICT-1 is evaluating licaminlimab in a phase 3 trial.
- Licaminlimab is a TNF-α inhibitor being developed for TNFR1-mediated dry eye disease.
- The trial includes patients positive for a specified TNFR1 genetic variant.
- Approximately two-thirds of PREDICT-1 participants are expected to have the specified TNFR1 genotype.
- In the interview, Oculis CEO Riad Sherif said topline results were expected around year-end.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
PREDICT-1 includes patients with dry eye disease, including patients positive for a specified TNFR1 genetic variant; approximately two-thirds of participants are expected to have this genotype.
Licaminlimab is being evaluated as a TNF-α inhibitor. The source provides no prescribing instructions, dose, or treatment outcomes.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.